Transcode Therapeutics Inc
RNAZ8.910USD
-1.060-10.63%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
7.43MValor de mercado
PerdaP/L TTM
Mais detalhes de Transcode Therapeutics Inc Empresa
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
Informações de Transcode Therapeutics Inc
Código da empresaRNAZ
Nome da EmpresaTranscode Therapeutics Inc
Data de listagemApr 28, 2021
CEOCalais (Philippe P)
Número de funcionários7
Tipo de títulosOrdinary Share
Fim do ano fiscalApr 28
Endereço6 Liberty Square
CidadeBOSTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02109
Telefone18573016857
Sitehttps://www.transcodetherapeutics.com/
Código da empresaRNAZ
Data de listagemApr 28, 2021
CEOCalais (Philippe P)
Executivos da empresa Transcode Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
2.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
1.00
+1.00%
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
2.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
1.00
+1.00%
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: sex, 9 de jan
Atualizado em: sex, 9 de jan
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
CK Life Sciences International Holdings, Inc.
9.08%
Sabby Management, LLC
4.54%
DRW Securities, LLC
1.28%
The Vanguard Group, Inc.
0.71%
Geode Capital Management, L.L.C.
0.58%
Outro
83.82%
Investidores
Investidores
Proporção
CK Life Sciences International Holdings, Inc.
9.08%
Sabby Management, LLC
4.54%
DRW Securities, LLC
1.28%
The Vanguard Group, Inc.
0.71%
Geode Capital Management, L.L.C.
0.58%
Outro
83.82%
Tipos de investidores
Investidores
Proporção
Corporation
9.08%
Investment Advisor/Hedge Fund
5.11%
Investment Advisor
2.31%
Research Firm
0.28%
Individual Investor
0.14%
Hedge Fund
0.02%
Outro
83.06%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
36
70.82K
7.72%
-29.38K
2025Q3
37
40.93K
4.61%
-48.04K
2025Q2
41
77.84K
18.97%
+69.48K
2025Q1
45
80.09K
9.69%
+74.47K
2024Q4
36
155.76K
22.37%
+143.23K
2024Q3
40
10.06K
1.97%
-8.53K
2024Q2
41
8.22K
4.45%
-5.03K
2024Q1
41
12.92K
7.67%
+11.92K
2023Q4
41
826.00
4.24%
+40.00
2023Q3
39
727.00
50.61%
+276.00
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
CK Life Sciences International Holdings, Inc.
83.28K
9.08%
+83.28K
--
Oct 27, 2025
Sabby Management, LLC
41.60K
4.54%
+41.60K
--
Dec 31, 2025
DRW Securities, LLC
11.70K
1.28%
+11.70K
--
Sep 30, 2025
The Vanguard Group, Inc.
6.54K
0.71%
--
--
Nov 30, 2025
Geode Capital Management, L.L.C.
4.93K
0.54%
--
--
Nov 30, 2025
Citi Investment Research (US)
1.59K
0.17%
+1.59K
--
Sep 30, 2025
Tracy (Thomas Joseph)
1.25K
0.14%
+1.25K
--
Mar 07, 2025
Desjardins Securities Inc.
975.00
0.11%
+975.00
--
Sep 30, 2025
Tower Research Capital LLC
142.00
0.02%
-260.00
-64.68%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Apr 16, 2025
Merger
28→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Jan 11, 2024
Merger
40→1
Data
Data ex-dividendo
Tipo
Proporção
Apr 16, 2025
Merger
28→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Jan 11, 2024
Merger
40→1
Jan 11, 2024
Merger
40→1
Jan 11, 2024
Merger
40→1
Jan 11, 2024
Merger
40→1
May 22, 2023
Merger
20→1
Ver Mais
